OCULAR THERAPEUTIX, INC Interest on Convertible Debt, Net of Tax
OCULAR THERAPEUTIX, INC (OCUL) reported Interest on Convertible Debt, Net of Tax of $4.17 million for the 12-month period ending 2023-12-31, per its 10-K filed 2026-02-05.
Financial Statements › Notes
us-gaap:InterestOnConvertibleDebtNetOfTax · last filed 2026-02-05
- OCULAR THERAPEUTIX, INC interest on convertible debt, net of tax for the quarter ending 2023-12-31 was $940.00K, a 19.73% decline year-over-year.
- OCULAR THERAPEUTIX, INC interest on convertible debt, net of tax for the quarter ending 2023-09-30 was $1.00M, a 13.52% decline year-over-year.
- OCULAR THERAPEUTIX, INC interest on convertible debt, net of tax for the quarter ending 2022-12-31 was $1.17M, a 4.27% increase year-over-year.
- OCULAR THERAPEUTIX, INC interest on convertible debt, net of tax for the quarter ending 2022-09-30 was $1.16M, a 4.31% increase year-over-year.
- OCULAR THERAPEUTIX, INC interest on convertible debt, net of tax for fiscal 2023 was $4.17M, a 9.23% decline from fiscal 2022.
- OCULAR THERAPEUTIX, INC interest on convertible debt, net of tax for fiscal 2022 was $4.60M, a 4.24% increase from fiscal 2021.
- OCULAR THERAPEUTIX, INC interest on convertible debt, net of tax for fiscal 2021 was $4.41M.
| Period end | Interest on Convertible Debt, Net of Tax 3 month | Interest on Convertible Debt, Net of Tax 6 month | Interest on Convertible Debt, Net of Tax 9 month | Interest on Convertible Debt, Net of Tax 12 month |
|---|---|---|---|---|
| 2023-12-31 | $940.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-05 | $1.94M derived: sum of 2 quarters · filed 2026-02-05 | $4.17M 10-K · filed 2026-02-05 | |
| 2023-09-30 | $1.00M 10-Q · filed 2024-11-14 | $3.23M 10-Q · filed 2024-11-14 | ||
| 2022-12-31 | $1.17M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-03 | $2.33M derived: sum of 2 quarters · filed 2025-03-03 | $3.47M derived: sum of 3 quarters · filed 2025-03-03 | $4.60M 10-K · filed 2025-03-03 |
| 2022-09-30 | $1.16M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-07 | $2.30M derived: sum of 2 quarters · filed 2023-11-07 | $3.42M 10-Q · filed 2023-11-07 | $4.55M derived: sum of 4 quarters · filed 2024-03-11 |
| 2022-06-30 | $1.14M 10-Q · filed 2023-08-07 | $2.26M 10-Q · filed 2023-08-07 | $3.39M derived: sum of 3 quarters · filed 2024-03-11 | $4.50M derived: sum of 4 quarters · filed 2024-03-11 |
| 2022-03-31 | $1.12M 10-Q · filed 2023-05-08 | $2.25M derived: sum of 2 quarters · filed 2024-03-11 | $3.36M derived: sum of 3 quarters · filed 2024-03-11 | $4.45M derived: sum of 4 quarters · filed 2024-03-11 |
| 2021-12-31 | $1.12M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-11 | $2.24M derived: sum of 2 quarters · filed 2024-03-11 | $3.33M derived: sum of 3 quarters · filed 2024-03-11 | $4.41M 10-K · filed 2024-03-11 |
| 2021-09-30 | $1.11M 10-Q · filed 2022-11-07 | $2.21M derived: sum of 2 quarters · filed 2022-11-07 | $3.29M 10-Q · filed 2022-11-07 | |
| 2021-06-30 | $1.09M 10-Q · filed 2022-08-08 | $2.17M 10-Q · filed 2022-08-08 | ||
| 2021-03-31 | $1.08M 10-Q · filed 2022-05-09 | |||
| 2020-09-30 | $1.07M 10-Q · filed 2021-11-08 | |||
| 2019-09-30 | $998.00K 10-Q · filed 2020-11-05 | |||
| 2019-03-31 | $356.00K 10-Q · filed 2020-05-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| Aurinia Pharmaceuticals Inc. (AUPH) | $2.207B | 7.18 | |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 | |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |